Retinal Disease Research
Eyepoint Inc. focuses on clinical research in retinal disorders affecting central vision, with studies centered on diabetic macular edema and wet age-related macular degeneration.
- Diabetic Macular Edema
- Wet Age-Related Macular Degeneration
- Macular pathology
Its research activity is concentrated in ophthalmology and the treatment of vision-threatening macular disease.
Vision Preservation and Visual Function
The sponsor’s trials are designed around outcomes in best corrected visual acuity, reflecting a strong interest in preserving and improving central visual function in patients with retinal disease.
- Best corrected visual acuity
- Central vision
- Visual impairment
These studies place emphasis on clinical endpoints relevant to day-to-day visual performance in ophthalmic care.
Intravitreal Therapeutics
Eyepoint Inc. is active in research involving intravitreal treatment approaches for retinal disease, including sustained ocular delivery strategies used in posterior segment disorders.
- Intravitreal inserts
- Ocular drug delivery
- Posterior segment therapy
Its therapeutic interest lies in treatments intended for chronic management of retinal vascular disease.
Anti-VEGF Comparator Studies
The sponsor’s trials compare its retinal therapy with established anti-vascular endothelial growth factor treatment, indicating a focus on clinically relevant alternatives in retina specialist practice.
- Aflibercept
- Anti-VEGF therapy
- Retinal vascular disorders
Research activity is directed toward treatment options for patients with macular edema and neovascular retinal disease.
